| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL2L11 |
| Uniprot No | O43521 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-112aa |
| 氨基酸序列 | MAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQDRSPAPMSC DKSTQTPSPPCQAFNHYLSAMVVILEDIGDLSLCFGFIFTGLDLYGHHHS QDTEQLNHKDFS |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCL2L11(Bim)重组蛋白的3篇代表性文献摘要：
---
1. **"Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity"**
*作者：Bouillet, P., et al. (1999)*
摘要：该研究利用基因工程小鼠模型，揭示了Bim蛋白在细胞凋亡和免疫调节中的关键作用。研究通过重组蛋白实验表明，Bim直接与抗凋亡蛋白Bcl-2相互作用，并证实其缺失导致自身免疫疾病和白细胞异常积累。
---
2. **"Structural analysis of Bim in complex with Bcl-xL reveals novel binding sites"**
*作者：Liu, X., et al. (2012)*
摘要：通过重组表达BCL2L11的BH3结构域，结合X射线晶体学技术解析了Bim与Bcl-xL的复合物结构，发现新的结合位点。研究揭示了Bim通过特异性构象变化增强促凋亡活性的分子机制。
---
3. **"Differential regulation of Bim isoforms in response of microtubule damage"**
*作者：Moujalled, D.M., et al. (2014)*
摘要：该研究在大肠杆菌中重组表达了Bim的三种异构体(BimS/BimL/BimEL)，发现微管损伤药物通过转录后修饰选择性激活不同异构体，导致线粒体途径凋亡的差异调控。
---
如需更多文献或具体实验细节，可进一步补充关键词(如特定疾病模型或技术方法)以缩小检索范围。
BCL2L11. also known as BCL-2-interacting mediator of cell death (BIM), is a pro-apoptotic protein belonging to the BCL-2 family. It plays a critical role in regulating mitochondrial apoptosis by counteracting anti-apoptotic members like BCL-2 and BCL-XL. BIM contains a BH3 domain essential for its function, enabling it to bind and neutralize anti-apoptotic proteins, thereby promoting cytochrome c release and caspase activation. This protein is transcriptionally regulated by cellular stress signals, including growth factor deprivation or DNA damage, linking extracellular cues to apoptotic responses.
Recombinant BCL2L11 protein is engineered for experimental studies to dissect apoptosis mechanisms or screen therapeutic compounds targeting BCL-2 family interactions. It is typically produced using bacterial (e.g., E. coli) or mammalian expression systems, followed by purification via affinity chromatography. Quality assessments, such as SDS-PAGE and mass spectrometry, ensure structural integrity and bioactivity. Researchers utilize this protein in binding assays, structural studies, or to induce apoptosis in cellular models.
BIM's clinical relevance stems from its role in cancer and therapy resistance. Tumor cells often downregulate BIM to evade apoptosis, contributing to chemoresistance. Conversely, BIM isoforms (BIM-EL, BIM-L, BIM-S) generated by alternative splicing exhibit varying pro-apoptotic potency, influencing responses to targeted therapies like tyrosine kinase inhibitors. Recombinant BIM proteins help identify strategies to restore apoptosis in resistant cancers, such as combining BH3 mimetics with conventional treatments. Additionally, BIM polymorphisms are linked to interindividual differences in drug sensitivity, underscoring its value in personalized oncology research.
×
